129 related articles for article (PubMed ID: 37845541)
1. RNA interference treatment targeting angiotensinogen lowers blood pressure.
Carvalho T
Nat Med; 2023 Dec; 29(12):2962-2963. PubMed ID: 37845541
[No Abstract] [Full Text] [Related]
2. Small Interfering RNA Therapeutics in Hypertension: A Viewpoint on Vasopressor and Vasopressor-Sparing Strategies for Counteracting Blood Pressure Lowering by Angiotensinogen-Targeting Small Interfering RNA.
Ranasinghe P; Addison ML; Webb DJ
J Am Heart Assoc; 2022 Oct; 11(20):e027694. PubMed ID: 36216481
[No Abstract] [Full Text] [Related]
3. A growing chain of evidence linking genetic variation in angiotensinogen with essential hypertension: focus on "a haplotype of human angiotensinogen gene containing -217A increases blood pressure in transgenic mice compared with -217G," by Jain et al.
Sigmund CD
Am J Physiol Regul Integr Comp Physiol; 2008 Dec; 295(6):R1846-8. PubMed ID: 18971347
[No Abstract] [Full Text] [Related]
4. Conventional Vasopressor and Vasopressor-Sparing Strategies to Counteract the Blood Pressure-Lowering Effect of Small Interfering RNA Targeting Angiotensinogen.
Uijl E; Ye D; Ren L; Mirabito Colafella KM; van Veghel R; Garrelds IM; Lu HS; Daugherty A; Hoorn EJ; Nioi P; Foster D; Danser AHJ
J Am Heart Assoc; 2022 Aug; 11(15):e026426. PubMed ID: 35876413
[TBL] [Abstract][Full Text] [Related]
5. Blood pressure-independent renoprotective effects of small interference RNA targeting liver angiotensinogen in experimental diabetes.
Cruz-López EO; Ren L; Uijl E; Clahsen-van Groningen MC; van Veghel R; Garrelds IM; Domenig O; Poglitsch M; Zlatev I; Rooney T; Kasper A; Nioi P; Foster D; Danser AHJ
Br J Pharmacol; 2023 Jan; 180(1):80-93. PubMed ID: 36106615
[TBL] [Abstract][Full Text] [Related]
6. Targeting of hepatic angiotensinogen using chemically modified siRNAs results in significant and sustained blood pressure lowering in a rat model of hypertension.
Olearczyk J; Gao S; Eybye M; Yendluri S; Andrews L; Bartz S; Cully D; Tadin-Strapps M
Hypertens Res; 2014 May; 37(5):405-12. PubMed ID: 24335718
[TBL] [Abstract][Full Text] [Related]
7. Angiotensinogen gene polymorphism near transcription start site and blood pressure: role of a T-to-C transition at intron I.
Ishigami T; Tamura K; Fujita T; Kobayashi I; Hibi K; Kihara M; Toya Y; Ochiai H; Umemura S
Hypertension; 1999 Sep; 34(3):430-4. PubMed ID: 10489389
[TBL] [Abstract][Full Text] [Related]
8. Nanoparticle-mediated RNA interference of angiotensinogen decreases blood pressure and improves myocardial remodeling in spontaneously hypertensive rats.
Yuan LF; Sheng J; Lu P; Wang YQ; Jin T; Du Q
Mol Med Rep; 2015 Sep; 12(3):4657-4663. PubMed ID: 26062941
[TBL] [Abstract][Full Text] [Related]
9. Antisense oligonucleotides targeting angiotensinogen: insights from animal studies.
Wu CH; Wang Y; Ma M; Mullick AE; Crooke RM; Graham MJ; Daugherty A; Lu HS
Biosci Rep; 2019 Jan; 39(1):. PubMed ID: 30530571
[TBL] [Abstract][Full Text] [Related]
10. Strong and Sustained Antihypertensive Effect of Small Interfering RNA Targeting Liver Angiotensinogen.
Uijl E; Mirabito Colafella KM; Sun Y; Ren L; van Veghel R; Garrelds IM; de Vries R; Poglitsch M; Zlatev I; Kim JB; Hoorn EJ; Foster D; Danser AHJ
Hypertension; 2019 Jun; 73(6):1249-1257. PubMed ID: 31030610
[TBL] [Abstract][Full Text] [Related]
11. Delivery of therapeutic AGT shRNA by PEG-Bu for hypertension therapy.
Wang YQ; Wang F; Deng XQ; Sheng J; Chen SY; Su J
PLoS One; 2013; 8(7):e68651. PubMed ID: 23894329
[TBL] [Abstract][Full Text] [Related]
12. Gene trapping uncovers sex-specific mechanisms for upstream stimulatory factors 1 and 2 in angiotensinogen expression.
Park S; Liu X; Davis DR; Sigmund CD
Hypertension; 2012 Jun; 59(6):1212-9. PubMed ID: 22547438
[TBL] [Abstract][Full Text] [Related]
13. Novel Pharmacological Approaches in the Treatment of Hypertension: A Focus on RNA-Based Therapeutics.
Addison ML; Ranasinghe P; Webb DJ
Hypertension; 2023 Nov; 80(11):2243-2254. PubMed ID: 37706295
[TBL] [Abstract][Full Text] [Related]
14. Knockdown of angiotensinogen by shRNA-mediated RNA interference inhibits human visceral preadipocytes differentiation.
Ye ZW; Wu XM; Zhang LJ; Huang ZL; Jiang JG
Int J Obes (Lond); 2010 Jan; 34(1):157-64. PubMed ID: 19786968
[TBL] [Abstract][Full Text] [Related]
15. Novel mechanism of hypertension revealed by cell-specific targeting of human angiotensinogen in transgenic mice.
Davisson RL; Ding Y; Stec DE; Catterall JF; Sigmund CD
Physiol Genomics; 1999 Jul; 1(1):3-9. PubMed ID: 11015555
[TBL] [Abstract][Full Text] [Related]
16. Angiotensinogen gene variation associated with variation in blood pressure in aboriginal Canadians.
Hegele RA; Harris SB; Hanley AJ; Sun F; Connelly PW; Zinman B
Hypertension; 1997 May; 29(5):1073-7. PubMed ID: 9149668
[TBL] [Abstract][Full Text] [Related]
17. Analysis of Met235 to Thr variant of the angiotensinogen gene in relation to the blood pressure and family history of essential hypertension in Japanese children.
Kataoka S; Hashimoto N; Kakihara T; Tanaka A; Kawasaki T; Kikuchi T; Takahashi H; Uchiyama M
Acta Paediatr Jpn; 1996 Aug; 38(4):312-6. PubMed ID: 8840536
[TBL] [Abstract][Full Text] [Related]
18. Genetics of human hypertension, the role of angiotensinogen. should it be one of the drug target genes?
Kolovou GD; Mavrogeni S
Angiology; 2014 Apr; 65(4):269-71. PubMed ID: 23719091
[No Abstract] [Full Text] [Related]
19. Emerging insights and future prospects for therapeutic application of siRNA targeting angiotensinogen in hypertension.
Addison ML; Ranasinghe P; Webb DJ
Expert Rev Clin Pharmacol; 2023; 16(11):1025-1033. PubMed ID: 37897397
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular consequences of genetic variation at -6/235 in human angiotensinogen using "humanized" gene-targeted mice.
Grobe JL; Dickson ME; Park S; Davis DR; Born EJ; Sigmund CD
Hypertension; 2010 Nov; 56(5):981-7. PubMed ID: 20823378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
